Meeting
2024 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
Authors
Jonathan Alexander Chatzkel
University of Florida/UF Health Cancer Center, Gainesville, FL
Jonathan Alexander Chatzkel , Ji-Hyun Lee , Azka Ali , Carmen J. Allegra , Paul Crispen , Padraic O'Malley , Thomas J. George , Brian Hemendra Ramnaraign
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05000294
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS257)
DOI
10.1200/JCO.2024.42.4_suppl.TPS257
Abstract #
TPS257
Poster Bd #
Q18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
First Author: Brian Hemendra Ramnaraign
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
First Author: Brian Hemendra Ramnaraign